BioLine RX Stock

BioLine RX Book Value per Share

Delisted

The Book Value per Share of BioLine RX (BLRX.TA) as of Aug 23, 2026 is 0.01 USD. In the previous year, Book Value per Share was 0.01 USD — a change of 1.80% (higher).

Book Value per Share

0.01USD

YoY

1.80%

Last updated:

Book Value per Share of BioLine RX is 2026 0.01 USD. Book Value per Share of BioLine RX was 2025 0.01 USD. It decreases by 1.80% higher compared to the previous year.

The BioLine RX Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2017
0.04 USD
Jan 1, 2018
0.03 USD
Jan 1, 2019
0.03 USD
Jan 1, 2020
0.02 USD
Jan 1, 2021
0.06 USD
Jan 1, 2022
0.04 USD
Jan 1, 2023
0.01 USD
Jan 1, 2024
0.01 USD
The BioLine RX Book Value per Share history
YEARBook Value per ShareYoY
0.01USD+1.80%
0.01USD-73.99%
0.04USD-25.33%
0.06USD+209.06%
0.02USD-34.00%
0.03USD-19.22%
0.03USD-21.86%
0.04USD+50.97%
0.03USD-26.43%
0.04USD+49.69%
0.03USD—
Access this data via the Eulerpool API
Get Free API Key

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLine RX stock

Book Value per Share of BioLine RX is 0.01 USD in 2026.

Book Value per Share of BioLine RX changed from 0.01 USD to 0.01 USD, representing a 1.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share BioLine RX since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — BioLine RX

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BioLine RX